IL157256A0 - Methods and reagents for the rapid and efficient isolation of circulating cancer cells - Google Patents

Methods and reagents for the rapid and efficient isolation of circulating cancer cells

Info

Publication number
IL157256A0
IL157256A0 IL15725602A IL15725602A IL157256A0 IL 157256 A0 IL157256 A0 IL 157256A0 IL 15725602 A IL15725602 A IL 15725602A IL 15725602 A IL15725602 A IL 15725602A IL 157256 A0 IL157256 A0 IL 157256A0
Authority
IL
Israel
Prior art keywords
reagents
rapid
methods
cancer cells
circulating cancer
Prior art date
Application number
IL15725602A
Original Assignee
Immunivest Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunivest Corp filed Critical Immunivest Corp
Publication of IL157256A0 publication Critical patent/IL157256A0/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Power Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15725602A 2001-02-16 2002-02-19 Methods and reagents for the rapid and efficient isolation of circulating cancer cells IL157256A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26885901P 2001-02-16 2001-02-16
US26927001P 2001-02-20 2001-02-20
US26927101P 2001-02-20 2001-02-20
PCT/US2002/005233 WO2003065042A1 (en) 2001-02-16 2002-02-19 Methods and reagents for the rapid and efficient isolation of circulating cancer cells

Publications (1)

Publication Number Publication Date
IL157256A0 true IL157256A0 (en) 2004-02-19

Family

ID=27670560

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15725602A IL157256A0 (en) 2001-02-16 2002-02-19 Methods and reagents for the rapid and efficient isolation of circulating cancer cells

Country Status (8)

Country Link
EP (1) EP1360496A4 (en)
JP (1) JP2005516217A (en)
KR (1) KR20030080002A (en)
AU (2) AU2002306561A2 (en)
BR (1) BR0207290A (en)
CA (1) CA2438112A1 (en)
IL (1) IL157256A0 (en)
WO (1) WO2003065042A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
EP1597353B1 (en) 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
EP1673611A4 (en) * 2003-09-18 2011-11-30 Immunivest Corp Operator independent programmable sample preparation and analysis system
ES2521620T3 (en) * 2004-03-03 2014-11-13 Universidad De Salamanca Method for multidimensional detection of aberrant phenotypes in neoplastic cells for use to monitor minimum disease levels using flow cytometry
US20080261243A1 (en) * 2004-10-06 2008-10-23 Wellstat Biologics Corporation Detection of Elevated Levels of Her-2/Neu Protein on Circulating Cancer Cells and Treatment
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
CN1772303A (en) * 2005-10-25 2006-05-17 朱宏 Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor
US7842465B2 (en) * 2006-01-17 2010-11-30 Palo Alto Research Center Incorporated Immunocytostaining methods for enhanced dye ratio discrimination in rare event detection
WO2007095644A2 (en) * 2006-02-16 2007-08-23 Ventana Medical Systems, Inc. Reagents and methods for cancer prognosis and pathological staging
JP2009529878A (en) * 2006-03-13 2009-08-27 ベリデックス・エルエルシー Primary cell proliferation
WO2007121465A2 (en) 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
JP5078100B2 (en) * 2006-04-18 2012-11-21 ウェルスタット バイオロジクス コーポレイション Detection and treatment of steroid receptors in circulating cancer cells
KR20090023423A (en) * 2006-06-02 2009-03-04 화이자 프로덕츠 인코포레이티드 Circulating tumor cell assay
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp Methods and compositions for detecting rare cells from a biological sample
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
JP5923035B2 (en) 2009-03-24 2016-05-24 バイオセプト インコーポレイティッド Devices and methods for cell capture and analysis
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
DE102009047146B4 (en) 2009-11-25 2012-07-19 Ulrich Pachmann A method for predicting the response of a tumor disease to a therapeutic intervention
BR112012031860A8 (en) 2010-06-17 2016-09-13 Koninklijke Philips Nv METHOD FOR DETECTING A BIOLOGICAL TARGET IN AN AFFINITY ASSAY, DETECTION ARRANGEMENT FOR A BIOLOGICAL TARGET AND CAPTURE PORTION FOR USE IN A METHOD
EP2591363B1 (en) 2010-07-07 2017-09-20 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
KR101988600B1 (en) 2011-06-29 2019-06-12 가부시키가이샤 엘에스아이 메디엔스 Non-specific reaction inhibitor, and method and kit for inhibiting non-specific reaction
EP2786151B1 (en) 2011-11-29 2019-07-03 F.Hoffmann-La Roche Ag Methods for prostate cancer analysis
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
CN102914650B (en) * 2012-06-14 2014-11-05 北京大成生物工程有限公司 Quantitative detection kit for neuronspecific enolase (NSE) and preparation method and application thereof
WO2014138183A1 (en) 2013-03-05 2014-09-12 Board Of Regents, The University Of Texas System Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells
CN104561246B (en) * 2013-10-18 2018-06-15 深圳先进技术研究院 The method and kit of the detection signal amplification of circulating cancer cells in blood
JP6582486B2 (en) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 Method for detecting rare cells in blood
KR101723072B1 (en) 2016-12-29 2017-04-05 주식회사 지노바이오 Cell separation system
WO2017142190A1 (en) 2016-02-18 2017-08-24 주식회사 지노바이오 Cell separation chip and system
KR101723082B1 (en) 2016-12-29 2017-04-05 주식회사 지노바이오 Cell Separator
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
CN110669823B (en) * 2018-07-03 2022-05-24 中国医学科学院肿瘤医院 ctDNA library construction and sequencing data analysis method for simultaneously detecting multiple liver cancer common mutations
JP6935883B2 (en) * 2018-07-13 2021-09-15 五稜化薬株式会社 Pretreatment method for fluorescence image diagnosis
CN114958748B (en) * 2022-04-24 2024-02-13 东北大学 Nanometer magnetic affinity material for efficiently capturing and nondestructively releasing circulating tumor cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993829A (en) * 1987-04-23 1999-11-30 Bystryn; Jean-Claude Anti-cancer vaccine
US5512657A (en) * 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
ATE261314T1 (en) * 1992-07-22 2004-03-15 Univ Princeton P53 VACCINE
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
AU760560B2 (en) * 1998-02-12 2003-05-15 Board Of Regents, The University Of Texas System Methods and reagents for the rapid and efficient isolation of circulating cancer cells
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
JP2002526421A (en) * 1998-10-05 2002-08-20 ジェンザイム・コーポレーション Genes for cancer vaccine design differentially expressed in cancer cells
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use

Also Published As

Publication number Publication date
AU2008249153A1 (en) 2008-12-11
EP1360496A1 (en) 2003-11-12
KR20030080002A (en) 2003-10-10
WO2003065042A1 (en) 2003-08-07
JP2005516217A (en) 2005-06-02
AU2008249153B2 (en) 2012-05-10
CA2438112A1 (en) 2003-08-07
EP1360496A4 (en) 2005-03-09
BR0207290A (en) 2005-06-07
AU2002306561A2 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
IL157256A0 (en) Methods and reagents for the rapid and efficient isolation of circulating cancer cells
AU2002239826A1 (en) Methods and reagents for the isolation of nucleic acids
ZA200500985B (en) Isolation and identification of T cells.
EP1390747A4 (en) Systems and methods for automated analysis of cells and tissues
EP1385273A4 (en) Cell searcher and cell searching method
AU785425C (en) Methods of genomic analysis
IL152919A0 (en) Stabilized tetrazolium reagent compositions and methods for using the same
AU2003273542A8 (en) Methods of identifying and isolating stem cells and cancer stem cells
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
IL158368A0 (en) Methods and reagents for cell transplantation
EP1383801A4 (en) Antibodies against cancer
EP1425399A4 (en) Combinatorial methods for inducing cancer cell death
AU2002318203A1 (en) Space craft and methods for space travel
MXPA03003011A (en) Methods of inducing cancer cell death and tumor regression.
AU2002365228A1 (en) Antigen panels and methods of using the same
GB0111218D0 (en) Assays methods and means
WO2001009384A3 (en) Serial analysis of genetic alterations
GB2389532B (en) The method of treating cancer
EP1363637A4 (en) Pyrimidine compounds and methods for making and using the same
AU2409602A (en) Method of testing anticancer agent-sensitivity of tumor cells
IL157910A0 (en) Organic open cell foam and methods for the preparation thereof
EP1566639A4 (en) Method of examining cancer cells and reagent therefor
EP1454914A4 (en) Tumor antigen
AU2003200335A1 (en) Methods and reagents for the rapid and efficient isolation of circulating cancer cells
AU2003200334A1 (en) Methods and reagents for the rapid and efficient isolation of circulating cancer cells